The CLSI M22-A3 document has served as the cornerstone of quality control for commercially prepared microbiological culture media for nearly two decades. While US regulatory changes have shifted the compliance landscape since 2016, the standard remains a technically valid, FDA-recognized consensus standard that continues to guide international laboratories and support regulatory submissions.
The standard sets a clear cutoff for an acceptable failure rate at ≤0.5% , meaning no more than 5 out of 1000 units should demonstrate random defects.
: Common media types (like Blood Agar, Chocolate Agar, and MacConkey Agar) produced by manufacturers who follow strict QC protocols. Under M22-A3, laboratories using these commercially prepared batches do not need to perform full organism-based QC, provided they maintain documentation of the manufacturer's quality certification. clsi m22a3 pdf link
In the field of clinical microbiology, accuracy is non-negotiable. When a patient provides a sample for culture, the results dictate their treatment plan. To ensure these results are reliable, laboratories rely on standardized guidelines. One such critical standard is .
I can provide targeted breakdowns to keep your lab compliant. Share public link The CLSI M22-A3 document has served as the
It provides a universal benchmark that ensures consistent, high-quality results across different healthcare facilities.
The CLSI M22A3 guidelines are a critical resource for laboratories and healthcare professionals involved in blood culture testing. By following these guidelines, laboratories can ensure that they produce high-quality results, guiding antibiotic therapy and improving patient outcomes. The provided in this article allows easy access to the document, enabling users to review and implement the guidelines. By standardizing blood culture collection and processing procedures, we can improve the accuracy and reliability of test results, ultimately leading to better patient care. : Common media types (like Blood Agar, Chocolate
: By identifying "exempt" media, labs can significantly reduce the labor and cost of redundant testing while maintaining high safety standards. Global Consistency
Central to the M22-A3 framework is the concept of the Quality Control Maintenance Program. To utilize the exemptions provided by the guideline, a laboratory must maintain rigorous documentation. This includes verifying that the manufacturer is following CLSI standards, ensuring that media are transported and stored under appropriate conditions, and performing a visual inspection of every shipment for contamination, physical defects, or expiration. If a laboratory encounters a failure in a batch of exempt media, M22-A3 outlines the corrective actions and documentation necessary to report the failure to the manufacturer and, if necessary, reinstate internal testing until the issue is resolved.
Because CLSI standards are copyrighted materials, they are typically not available for free download as a full PDF. You can obtain official copies through the following platforms: